Umbralisib
Ukoniq (umbralisib) is a small molecule pharmaceutical. Umbralisib was first approved as Ukoniq on 2021-02-05. It is used to treat b-cell lymphoma marginal zone and follicular lymphoma in the USA. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. In addition, it is known to target casein kinase I isoform epsilon.
Download report
Favorite
FDA Novel Drug Approvals 2021
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Umbralisib tosylate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
UKONIQ | TG Therapeutics | N-213176 DISCN | 2021-02-05 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
ukoniq | New Drug Application | 2021-02-16 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
UMBRALISIB TOSYLATE, UKONIQ, TG THERAPS | |||
2026-02-05 | NCE |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Umbralisib Tosylate, Ukoniq, Tg Theraps | |||
9969740 | 2035-05-26 | DS, DP | U-3063, U-3064 |
10414773 | 2035-05-26 | DS, DP | U-3063, U-3064 |
10947244 | 2035-05-26 | U-3063, U-3064 | |
9150579 | 2033-07-02 | DS, DP | |
9669033 | 2033-07-02 | U-3063, U-3064 | |
10072013 | 2033-07-02 | U-3063, U-3064 | |
10570142 | 2033-07-02 | DS, DP | U-3063, U-3064 |
10981919 | 2033-07-02 | U-3063, U-3064 |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
Esophageal neoplasms | D004938 | C15 | 1 | — | — | — | — | 1 | |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
Rectal neoplasms | D012004 | 1 | — | — | — | — | 1 | ||
Polycythemia vera | D011087 | D45 | 1 | — | — | — | — | 1 | |
Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 1 | — | — | — | — | 1 |
T-cell lymphoma peripheral | D016411 | C84.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | UMBRALISIB |
INN | umbralisib |
Description | Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
|
Classification | Small molecule |
Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F |
Identifiers
PDB | — |
CAS-ID | 1532533-67-7 |
RxCUI | — |
ChEMBL ID | CHEMBL3948730 |
ChEBI ID | — |
PubChem CID | 72950888 |
DrugBank | DB14989 |
UNII ID | 38073MQB2A (ChemIDplus, GSRS) |
Target
Agency Approved
PIK3CD
PIK3CD
Organism
Homo sapiens
Gene name
PIK3CD
Gene synonyms
NCBI Gene ID
Protein name
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Protein synonyms
p110delta, Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta short variant 8/20, phosphoinositide-3-kinase C, phosphoinositide-3-kinase, catalytic, delta polypeptide variant p37delta, PI3-kinase p110 subunit delta, PI3Kdelta, PtdIns-3-kinase subunit p110-delta
Uniprot ID
Mouse ortholog
Pik3cd (18707)
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Q8CJ28)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 388 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,092 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more